Literature DB >> 8480472

Mortality in patients treated for hyperthyroidism with iodine-131.

P Hall1, G Lundell, L E Holm.   

Abstract

Causes of death were studied in 10,552 Swedish hyperthyroid patients treated with 131I diagnosed between 1950 and 1975. The patients were followed for an average of 15 years (range 0-35 years) and were matched with the Swedish Cause of Death Register. A total of 5,400 deaths were observed and the overall standardized mortality ratio was 1.47 (95% confidence interval (CI) 1.43-1.51). The standardized mortality ratio for females was 1.50 (95% CI 1.46-1.55) compared to 1.31 (95% CI 1.23-1.39) in males. The most common cause of death (61%) was from cardiovascular diseases (standardized mortality ratio 1.65; 95% CI 1.59-1.71). Significantly elevated risks were also seen for tumours, diseases of the endocrine system, respiratory system, gastro-intestinal system, and congenital malformations. In all causes of death, except tumours and trauma, decreasing standardized mortality ratios over time were seen. Patients followed for more than 10 years had significantly elevated risks for tumours, diseases of the endocrine, respiratory, and cardiovascular systems. Patients given higher 131I activity and younger patients had higher standardized mortality ratios than those given lower activity and older patients. The hyperthyroidism per se, rather than the 131I treatment, appeared to be the major explanation for the elevated mortality.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8480472     DOI: 10.1530/acta.0.1280230

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  11 in total

1.  EANM procedure guidelines for therapy of benign thyroid disease.

Authors:  Marcel P M Stokkel; Daria Handkiewicz Junak; Michael Lassmann; Markus Dietlein; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

2.  Effect of 9 months of vitamin D supplementation on arterial stiffness and blood pressure in Graves' disease: a randomized clinical trial.

Authors:  Diana Grove-Laugesen; Sofie Malmstroem; Eva Ebbehoj; Anne Lene Riis; Torquil Watt; Klavs Würgler Hansen; Lars Rejnmark
Journal:  Endocrine       Date:  2019-07-06       Impact factor: 3.633

3.  Excess mortality in hyperthyroidism: the influence of preexisting comorbidity and genetic confounding: a danish nationwide register-based cohort study of twins and singletons.

Authors:  Frans Brandt; Dorthe Almind; Kaare Christensen; Anders Green; Thomas Heiberg Brix; Laszlo Hegedüs
Journal:  J Clin Endocrinol Metab       Date:  2012-08-28       Impact factor: 5.958

Review 4.  Cardiovascular involvement in patients with different causes of hyperthyroidism.

Authors:  Bernadette Biondi; George J Kahaly
Journal:  Nat Rev Endocrinol       Date:  2010-06-29       Impact factor: 43.330

Review 5.  Thyroid cancer following exposure to radioactive iodine.

Authors:  J Robbins; A B Schneider
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

6.  Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome.

Authors:  Cihangir Erem; Nurten Kandemir; Arif Hacihasanoglu; Halil Onder Ersöz; Kubilay Ukinc; Mustafa Kocak
Journal:  Endocrine       Date:  2004-10       Impact factor: 3.633

7.  Arterial Stiffness and Blood Pressure in Patients Newly Diagnosed with Graves' Disease Compared with Euthyroid Controls.

Authors:  Diana Grove-Laugesen; Sofie Malmstroem; Eva Ebbehoj; Anne Lene Riis; Torquil Watt; Lars Rejnmark; Klavs Würgler Hansen
Journal:  Eur Thyroid J       Date:  2020-02-14

8.  Duration of thyroid dysfunction correlates with all-cause mortality. the OPENTHYRO Register Cohort.

Authors:  Anne Sofie Laulund; Mads Nybo; Thomas Heiberg Brix; Bo Abrahamsen; Henrik Løvendahl Jørgensen; Laszlo Hegedüs
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

9.  Recovery following Thyroxine Treatment Withdrawal, but Not Propylthiouracil, Averts In Vivo and Ex Vivo Thyroxine-Provoked Cardiac Complications in Adult FVB/N Mice.

Authors:  Nancy S Saad; Steven J Repas; Kyle Floyd; Paul M L Janssen; Mohammad T Elnakish
Journal:  Biomed Res Int       Date:  2017-07-16       Impact factor: 3.411

10.  Should radioiodine now be first line treatment for Graves' disease?

Authors:  Onyebuchi E Okosieme; Peter N Taylor; Colin M Dayan
Journal:  Thyroid Res       Date:  2020-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.